Headlines about Abbott Laboratories (NYSE:ABT) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the healthcare product maker an impact score of 46.6103410466145 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have effected Accern’s rankings:

Abbott Laboratories (NYSE ABT) traded up $0.90 during mid-day trading on Monday, reaching $56.40. 6,053,871 shares of the company’s stock traded hands, compared to its average volume of 6,640,758. The stock has a market cap of $96,603.35, a PE ratio of 23.03, a P/E/G ratio of 2.08 and a beta of 1.06. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 12-month low of $37.90 and a 12-month high of $56.69.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. Abbott Laboratories’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 EPS. equities analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a $0.28 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 annualized dividend and a yield of 1.99%. The ex-dividend date of this dividend is Thursday, January 11th. Abbott Laboratories’s payout ratio is presently 83.47%.

A number of brokerages have issued reports on ABT. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Jefferies Group reaffirmed a “buy” rating and issued a $65.00 target price on shares of Abbott Laboratories in a report on Thursday, October 19th. Royal Bank of Canada increased their target price on shares of Abbott Laboratories from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Thursday, October 19th. Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, October 19th. Finally, Cowen set a $68.00 target price on shares of Abbott Laboratories and gave the company a “buy” rating in a report on Thursday, October 19th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $57.56.

In other Abbott Laboratories news, insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $54.92, for a total value of $1,555,279.48. Following the transaction, the insider now owns 102,117 shares in the company, valued at approximately $5,608,265.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the transaction, the insider now owns 58,739 shares in the company, valued at approximately $3,052,665.83. The disclosure for this sale can be found here. Insiders sold a total of 616,332 shares of company stock valued at $33,579,226 over the last ninety days. 0.76% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/abbott-laboratories-abt-earning-somewhat-favorable-press-coverage-study-finds/1771724.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.